Browse categories and answer follow-up questions to refine your symptom profile.
Approach to the Critical Patient
Immediate priorities
Airway and breathing threats
Right pleural effusion or empyema
Thoracic extension of abscess
Decreased breath sounds at right base
Oxygenation failure
SpO2 < 90% on room air
PaO2 < 60 mmHg
Diaphragmatic irritation
Right pleuritic chest pain
Referred right shoulder pain
Circulation and rupture threats
Shock physiology
SBP < 90 mmHg
MAP < 65 mmHg
Intraperitoneal rupture
Peritoneal signs
Abdominal rigidity and distention
Pericardial rupture from left-lobe abscess
Tamponade physiology
Muffled heart sounds and JVD
If hemodynamic instability with rupture, immediate resuscitation and surgical consult
Large-bore IV access
Type and crossmatch
Sepsis and source threats
Sepsis screening
Suspected infection with organ dysfunction
Lactate >= 2 mmol/l
Bacterial superinfection of abscess
No response after 4 to 5 days of metronidazole
Klebsiella and E. coli co-pathogens
If septic shock, broad spectrum antibiotics within 1 hour
Source control planning
Interventional radiology activation
Initial stabilization
Resuscitation bundle
IV crystalloid for hypoperfusion
Reassess after each bolus
Avoid over-resuscitation in pleural extension
Antipyretics for high fever
Acetaminophen first line
Avoid hepatotoxic dosing
Empiric tissue amebicide once ALA suspected
Metronidazole started promptly
Do not await serology if high pretest probability
Monitoring and targets
Continuous pulse oximetry
SpO2 target 92% to 96%
Trend with positioning
Cardiac monitor
Tachyarrhythmia from sepsis
Electrical alternans if tamponade
Serial abdominal reassessment
Expanding tenderness as rupture clue
New peritoneal signs
Immediate consults
Consultation triggers
Interventional radiology
Percutaneous aspiration or drainage
Diagnostic uncertainty with pyogenic abscess
Infectious disease
HIV co-infection
Treatment failure or complex disease
Surgery
Rupture with peritonitis
Pericardial involvement
History
Presentation pattern
Core syndrome
Fever
Present in 77% to 100% of cases
Night sweats
Right upper quadrant or epigastric pain
Constant dull aching quality
Pleuritic right chest component
Referred right shoulder pain
Diaphragmatic irritation source
Worse with deep inspiration
Onset and timeline
Subacute onset over 2 to 4 weeks
About 80% present in this window
Cough common at presentation
Delayed presentation after endemic exposure
Months to years after travel
Reactivation of latent infection
Associated symptoms
Gastrointestinal
Nausea and vomiting
Diarrhea in only 10% to 35%
Constitutional
Anorexia
Weight loss in chronic cases
Risk factors
Host and demographic factors
Male sex
Male to female ratio 10 to 12 : 1
Reproductive age 20 to 40 years
Alcohol consumption
One of the strongest associations
Confounds metronidazole therapy
Immunosuppression
HIV with CD4 < 100 cells/uL
Corticosteroids or transplant
Exposure and epidemiologic factors
Travel or residence in endemic areas
Indian subcontinent and Southeast Asia
Africa and Central and South America
Contaminated food or water
Untreated drinking water
Poor sanitation and crowding
Men who have sex with men
Increased risk with HIV co-infection
Fecal-oral sexual transmission
Institutional factors
Institutionalized populations
Group homes
Mental health facilities
Prior amebiasis
Recurrence if luminal carriage not eradicated
Incomplete prior treatment
Important clues and pitfalls
Distinguishing negatives
Jaundice usually absent
Presence suggests pyogenic abscess
Or biliary obstruction
Concurrent dysentery often absent
Stool microscopy usually negative
GI symptoms uncommon
Misdiagnosis risk
Correct ED diagnosis in only about 31.5% of cases
Cholecystitis most common misdiagnosis 16.4%
Hepatitis second most common 12.3%
Pneumonia mislabel in about 10%
Right lower lobe involvement
Cough and pleuritic pain dominant
Physical Exam
Vitals and general
Stability snapshot
Temperature
Fever in 77% to 100% of cases
High fever as severity marker
Heart rate
Tachycardia common
Rising trend with sepsis
Blood pressure
SBP < 90 mmHg suggests rupture or sepsis
MAP < 65 mmHg
General appearance
Ill and febrile
Diaphoresis
Discomfort with movement
Volume status
Dry mucosa if diarrhea
Tachycardia with hypovolemia
Abdominal and hepatic exam
Hallmark findings
Tender hepatomegaly
Point tenderness over the liver
Tenderness in intercostal spaces
Hepatic percussion tenderness
Below the right costal margin
Reproducible focal tenderness
Rupture screen
Peritoneal signs
Guarding and rebound
Rigidity as urgent escalation trigger
Abdominal distention
Free intraperitoneal fluid
New ascites
Pulmonary and cardiac exam
Right base findings
Dullness to percussion
Diaphragmatic irritation
Pleural effusion
Rales at right lung base
Decreased breath sounds
Reduced excursion
Cardiac findings with left-lobe disease
Pericardial involvement clues
Muffled heart sounds
Pulsus paradoxus
Tamponade physiology
Elevated JVP
Hypotension
Differential Diagnosis
Hepatic abscess and mass mimics
Pyogenic liver abscess
ICD-10 K75.0
Age over 50 years
Diabetes and biliary disease
Distinguishing features
Jaundice and multiple abscesses
Negative amebic serology
Hepatocellular carcinoma
Necrotic hepatoma
Cirrhosis or hepatitis B or C
Elevated alpha-fetoprotein
Imaging features
Arterial enhancement
Washout pattern
Echinococcal hydatid cyst
Usually incidental
Often afebrile
Eosinophilia possible
Aspiration caution
Anaphylaxis risk
Daughter cysts on imaging
Hepatic metastases
Known primary malignancy
Multiple lesions
Constitutional symptoms
Acute abdomen and thoracic mimics
Biliary and gastric
Acute cholecystitis
Most common ED misdiagnosis
Murphy sign and gallstones
Hepatitis
Second most common misdiagnosis
Marked transaminase elevation
Thoracic
Right lower lobe pneumonia
Misdiagnosed in about 10% of ALA
Consolidation on imaging
Pleural effusion or empyema
Primary pulmonary source
Versus thoracic extension of abscess
Key discriminators favoring ALA
Younger male with travel history
No jaundice or biliary disease
No diabetes
Positive amebic serology
Solitary right lobe lesion
Alcohol use association
Laboratory Tests
Hematology and inflammation
Complete blood count
Leukocytosis
Mild to moderate elevation
Without eosinophilia
Anemia
Mild and chronic disease pattern
Normocytic
Inflammatory markers
Elevated ESR
Nonspecific support
Trends with response
Elevated CRP
Baseline then trend
Falls with treatment response
Hepatic and metabolic panel
Liver function tests
Acute ALA pattern
Elevated ALT
Normal alkaline phosphatase
Chronic ALA pattern
Elevated alkaline phosphatase
Normal ALT
Bilirubin
Usually normal
Elevation suggests pyogenic abscess
Other chemistries
Albumin
Often low
Marker of chronicity
Renal function and electrolytes
Antibiotic dosing inputs
Diarrhea-related losses
Microbiology and serology
Amebic serology
Anti-E. histolytica antibodies
About 90% sensitive for ALA
May be negative in first week
Repeat if initially negative
Convert by second week
Persistent seropositivity in endemic areas limits specificity
Stool and antigen testing
Stool antigen for E. histolytica
Positive in under 50% of ALA cases
TechLab E. histolytica II distinguishes from E. dispar
Stool microscopy
Generally unhelpful
Negative does not exclude ALA
Aspirate and molecular testing
Aspirate studies
E. histolytica antigen and microscopy
Aerobic and anaerobic cultures
PCR of aspirate
Nested multiplex PCR highest yield about 50%
Versus 34% for serology in one study
Blood cultures
Rule out concurrent bacteremia
Identify pyogenic co-infection
Obtain before antibiotics when feasible
Diagnostic Tests
Scoring Systems
Severity and sepsis stratification
qSOFA
RR >= 22 per minute
SBP <= 100 mmHg
Altered mental status
SIRS criteria
Temperature and heart rate
WBC and respiratory rate
Lactate-based perfusion assessment
>= 2 mmol/l organ hypoperfusion
Repeat after resuscitation
Abscess risk descriptors
Size thresholds
Abscess > 5 cm high rupture risk
Left-lobe location pericardial risk
Limitations
No validated ALA-specific score
Clinical trajectory supersedes single value
ACEP Level C recommendation for adjunct use
MRI
MRI abdomen role
Excellent sensitivity
Rarely needed acutely
Problem solving for indeterminate lesions
Characterization indications
Differentiate abscess from tumor
Assess vascular or biliary involvement
Contraindications
Unstable patient
Non-compatible implants
CT
CT abdomen with contrast
Findings
Hypodense lesion with peripheral enhancement
Solitary right lobe predominance
Strengths
Equally sensitive to ultrasound
Better for complications and extension
Complication detection
Rupture and perihepatic fluid
Thoracic and pericardial extension
Limitations and guidance
Cannot reliably distinguish amebic from pyogenic
Clinical context and serology essential
ACEP Level C recommendation for complication assessment
Contrast considerations
Renal function assessment
Allergy history
Ultrasound
First-line imaging
Typical appearance
Solitary round or oval hypoechoic lesion
Right lobe with homogeneous internal echoes
Advantages
Bedside availability in the ED
Highly sensitive for detection
Limitations
Cannot distinguish amebic from pyogenic reliably
Operator dependent
Point-of-care ultrasound
Rapid detection
Liver lesion identification
Right pleural effusion screen
Procedural guidance
Aspiration planning
ACEP Level B recommendation for effusion identification
Disposition
Level of care selection
Admission indications
All newly diagnosed ALA generally admitted
Therapy initiation and monitoring
Imaging confirmation
Need for percutaneous drainage
Diagnostic uncertainty
Large or high-risk abscess
Inability to tolerate oral medications
Persistent vomiting
IV metronidazole requirement
ICU indications
Hemodynamic instability or sepsis
Vasopressor requirement
Rising lactate despite resuscitation
Signs of rupture
Peritonitis
Pericardial involvement
Discharge criteria and follow up
Discharge criteria
Clinical improvement
Afebrile and improving pain
Tolerating oral medications
Safe outpatient plan
Reliable follow-up arranged
Luminal agent prescribed for completion
Follow up plan
Clinical reassessment within 1 to 2 weeks
Repeat imaging not routine if improving
Radiologic resolution takes 3 to 9 months
Specialist linkage
Infectious disease for complex cases
Ensure luminal eradication
Treatment
Initial stabilization
Supportive measures
IV fluids for hypoperfusion
Crystalloid boluses
Reassess perfusion
Antipyretics and analgesia
Acetaminophen
Avoid hepatotoxic dosing
Hemodynamic monitoring if septic
Continuous vitals
Lactate trend
Medical therapy
Tissue amebicide mainstay
Metronidazole
750 mg PO or IV every 8 hours for 7 to 10 days
Class I recommendation as first-line therapy
Cure rates approach 95%
Tinidazole alternative
2 g PO daily for 3 to 5 days
Better tolerated and shorter course
Not always available in the US
Expected response
Fever and pain improve within 72 to 96 hours
More than 50% size reduction within 1 week
Luminal agent after tissue amebicide
Paromomycin
25 to 35 mg/kg/day divided every 8 hours for 7 days
Start after completing metronidazole
Do not give concurrently with metronidazole
Diloxanide furoate
Second-line luminal option
Eradicates intestinal carriage
Rationale
Eliminates luminal colonization
Prevents relapse
Adjunctive antibiotics
Empiric broad-spectrum if bacterial co-infection
Cover Klebsiella and E. coli
Add when superinfection suspected
Avoid alcohol
Disulfiram-like reaction with metronidazole
During and 48 to 72 hours after therapy
Drainage and procedures
Percutaneous aspiration or drainage indications
Diagnostic uncertainty
Cannot exclude pyogenic abscess
Suspected bacterial superinfection
No response to metronidazole after 4 to 5 days
Persistent fever or pain
Reassess for complications
High-risk abscess
Large left-lobe lesion with pericardial risk
Abscess > 5 cm with imminent rupture risk
Severely ill patients
Image-guided drainage plus metronidazole
Combined approach for selected cases
Surgical intervention
Rarely needed
Reserved for rupture with peritonitis
Unresponsive to percutaneous drainage
Monitoring and reassessment
Response checkpoints
Day 4 to 5 reassessment
Clinical improvement expected
If not improving consider drainage or alternative diagnosis
Adverse effect surveillance
Metallic taste and nausea
Peripheral neuropathy with prolonged use
Treatment completion
Ensure full metronidazole course
Then luminal agent
Confirm adherence plan
Dose adjustment
Severe hepatic impairment
Monitor for QT prolongation at high doses
Special Populations
Pregnancy
Pregnancy considerations
Antimicrobial selection
Metronidazole used when benefits outweigh risks
Avoid in first trimester when possible
Luminal agent
Paromomycin poorly absorbed and preferred
Defer until after delivery if stable
Imaging approach
Ultrasound first-line
CT only when essential
Maternal monitoring
Maintain oxygenation
Fetal monitoring when viable
Geriatric
Older adult features
Atypical presentation
Blunted fever response
Higher index for pyogenic abscess
Overlapping comorbidity
Diabetes and biliary disease
Broaden differential
Medication risk
Renal and hepatic dosing adjustment
QT prolongation risk higher
Disposition bias toward admission
Frailty
Limited home supports
Pediatrics
Pediatric differences
Epidemiology
Endemic exposure and malnutrition
Multiple and larger abscesses with low CD4
Weight-based dosing
Metronidazole 35 to 50 mg/kg/day divided every 8 hours
Paromomycin 25 to 35 mg/kg/day divided every 8 hours
Severity markers
Feeding intolerance
Dehydration from diarrhea
Monitoring
Growth and nutrition
Family hygiene counseling
Background
Epidemiology
Frequency and burden
Most common extraintestinal amebiasis
Hematogenous portal spread of trophozoites
Entamoeba histolytica etiology
Demographic distribution
Male predominance 10 to 12 : 1
Reproductive age 20 to 40 years
Geographic burden
Endemic in Indian subcontinent and Southeast Asia
Africa and Central and South America
Outcomes
Mortality
Less than 1% with early treatment
Cure rates approach 95%
Severity stratification
Uncomplicated majority
Complicated with rupture or superinfection
Pathophysiology
Mechanisms
Colonic invasion
Trophozoites breach colonic mucosa
Flask-shaped ulcers
Portal dissemination
Hematogenous spread via portal vein
Right lobe predominance
Tissue necrosis
Liquefactive hepatic necrosis
Anchovy-paste abscess contents
Complication pathways
Direct extension
Thoracic and pleural extension
Pericardial extension from left lobe
Rupture and secondary infection
Intraperitoneal rupture
Bacterial superinfection and biliary fistula
Therapeutic Considerations
Treatment strategy principles
Two-step regimen
Tissue amebicide then luminal agent
Sequential not concurrent administration
Medical therapy first
Drainage adds no benefit in uncomplicated cases
Reserve drainage for defined indications
Relapse prevention
Complete luminal eradication
Confirm adherence
Diagnostic strategy
Serology plus imaging integration
Imaging cannot distinguish amebic from pyogenic
Serology about 90% sensitive
Emerging diagnostics
Aspirate PCR highest yield
Metagenomic next-generation sequencing when conventional tests negative
Prevention
Safe water and food hygiene
Fecal-oral transmission prevention
Sanitation improvement
Alcohol counseling
Strong association with ALA
Avoid during therapy
Patient Discharge Instructions
copy discharge instructions
Amebic liver abscess home care
Take all antibiotics exactly as prescribed until finished
Complete the second medicine that clears the intestine even after you feel well
No alcohol during treatment and for at least 3 days after
Rest and drink plenty of fluids
Warning signs to return to the ER
Worsening or returning fever after improvement
Increasing belly pain, hardness, or swelling
Chest pain or trouble breathing
Lightheadedness or fainting
Yellowing of the skin or eyes
Vomiting that prevents keeping fluids down
Expected recovery
Fever and pain should ease within 3 to 4 days
Contact your clinician if not improving by day 4 or 5
The abscess shrinks slowly over several months on scans
Follow up and prevention
Clinic follow-up within 1 to 2 weeks
Use safe drinking water and wash food well
Practice good hand hygiene to prevent reinfection
References
Guidelines and key sources
Key reviews and studies
Kumar R et al. Amebic Liver Abscess: An Update. World Journal of Hepatology 2024
Haque R et al. Amebiasis. New England Journal of Medicine 2003
Stanley SL. Amoebiasis. Lancet 2003
Diagnostic and imaging evidence
Ralls PW et al. Sonographic Features of Amebic and Pyogenic Liver Abscesses 1987
Lodhi S et al. Features Distinguishing Amoebic From Pyogenic Liver Abscess: 577 Adult Cases 2004
Hoffner RJ et al. Common Presentations of Amebic Liver Abscess. Annals of Emergency Medicine 1999
Treatment and microbiology evidence
Chavez-Tapia NC et al. Cochrane review percutaneous procedure plus metronidazole versus metronidazole alone 2009
Miller JM et al. IDSA and ASM Microbiology Laboratory Utilization Guide 2024
Gupta S et al. Amebiasis and Amebic Liver Abscess in Children. Pediatric Clinics of North America 2022
Coding standards
ICD-10 A06.4 amebic liver abscess
SNOMED CT amebic liver abscess disorder concept
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.